BlossomHill Therapeutics Reports $23.8 Million Net Loss in Q2 2026, IPO Raises $151.7 Million

BlossomHill Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $23.8 million for the quarter, compared to a loss of $13.2 million in the same period last year, marking an increase of 79% year-over-year. For the first half of 2026, the net loss totaled $44.8 million, up from $23.7 million in the first half of 2025. The increase in losses is attributed to heightened research and development expenses, which rose to $21.4 million in Q2 2026 from $12.5 million in Q2 2025, driven by expanded clinical trial activities and increased manufacturing costs.

The company’s total operating expenses for the second quarter of 2026 reached $24.7 million, a 75% increase from $14.1 million in the prior year. This rise is primarily due to increased spending on research and development, which accounted for $21.4 million of the total, reflecting the company's focus on advancing its clinical-stage product candidates, BH-30643 and BH-30236. General and administrative expenses also increased to $3.3 million from $1.6 million, driven by higher personnel and legal costs.

In terms of operational metrics, BlossomHill Therapeutics has made strides in its clinical programs. The company is advancing its lead candidate, BH-30643, which is currently in a global Phase 1/2 clinical trial for patients with EGFR-mutant non-small cell lung cancer. The trial is designed to evaluate the drug's efficacy against a range of EGFR mutations, including those resistant to existing therapies. The company has also initiated a Phase 1 trial for BH-30236, targeting acute myeloid leukemia and myelodysplastic syndromes. As of June 30, 2026, BlossomHill had cash and cash equivalents of $95.4 million, down from $136.7 million at the end of 2025, reflecting the cash burn associated with its clinical development activities.

Strategically, BlossomHill completed its initial public offering (IPO) in August 2026, raising approximately $151.7 million in net proceeds. This capital is expected to support the company’s operations into the second quarter of 2028. The IPO also facilitated the conversion of all outstanding convertible preferred stock into common stock, simplifying the company’s capital structure. Looking ahead, BlossomHill anticipates continued investment in its clinical programs and plans to report further data from its ongoing trials in the coming quarters. However, the company acknowledges the inherent risks in drug development and the need for additional funding to sustain its operations and development efforts.